Astellas Pharma Inc. (ALPMY)

Oncology Corporate Profile

Stock Performance

14.0500
-0.1400

HQ Location

Three Parkway North
Deerfield, IL 60015

Company Description

Astellas Pharma US, Inc., is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Located in Deerfield, Illinois, the company serves as the headquarters for the Americas and employs more than 2,300 people. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Website: http://www.astellas.us/

Brand Generic Indication
Tarceva®erlotinibTarceva® is a kinase inhibitor indicated for:

• Maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.

• Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

• First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
Xtandi®enzalutamideXtandi® is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
erlotinib tabletsHER1/EGFR tyrosine kinase inhibitor2nd line metastatic Non Small Cell Lung Cancer (NSCLC)IIIGenentech / Roche
gilteritinib / ASP2215tyrosine kinase inhibitorAcute Myelogenous Leukemia (AML)III
gilteritinib / ASP2215FLT3 tyrosine kinase inhibitorAcute Myelogenous Leukemia (AML)III
OSI-906dual IGF-1R and IR tyrosine kinase inhibitorAdrenocortical carcinoma (ACC)IIIOSI Pharmaceuticals
erlotinib tabletsHER1/EGFR tyrosine kinase inhibitorColorectal cancerIIIGenentech / Roche
enzalutamide / MDV3100androgen receptor inhibitorMetastatic hormone-sensitive Prostate cancerIII
ASP8273EGFR receptorNon Small Cell Lung Cancer (NSCLC)III
enzalutamide / MDV3100androgen receptor inhibitorNon-metastatic castration-resistant Prostate cancerIII
erlotinib tabletsHER1/EGFR tyrosine kinase inhibitorOvarian cancerIIIGenentech / Roche
ASP3550GnRH antagonistProstate cancerIII
enzalutamide / MDV3100androgen receptor inhibitorProstate cancer in patients with non-metastatic biochemical recurrenceIII
enzalutamide / MDV3100androgen receptor inhibitorTriple negative Breast cancerIII
YM155survivin suppressant1st line metastatic Breast cancerII
OSI-906dual IGF-1R and IR tyrosine kinase inhibitor1st line metastatic Hepatocellular carcinoma (HCC)IIOSI Pharmaceuticals
AGS-1C4D4anti-PSCA monoclonal antibody (humanized)1st line metastatic Pancreatic cancerII
quizartinib / AC220FLT3 tyrosine kinase inhibitor2nd line metastatic Acute Myelogenous Leukemia (AML)IIAmbit Biosciences Inc.
blinatumomab / AMG 103anti-CD19 monoclonal antibodyAcute Lymphocytic Leukemia (ALL)II
YM155survivin suppressantB-cell Non-Hodgkin's Lymphoma (NHL)II
enzalutamide / MDV3100androgen receptor inhibitorBreast cancerII
enzalutamide / MDV3100androgen receptor inhibitorHepatocellular carcinoma (HCC)II
YM155survivin suppressantMelanomaII
OSI-906dual IGF-1R and IR tyrosine kinase inhibitorNon Small Cell Lung Cancer (NSCLC)IIOSI Pharmaceuticals
OSI-906dual IGF-1R and IR tyrosine kinase inhibitorOvarian cancerIIOSI Pharmaceuticals
AGS-16C3Fantibody drug conjugate (ADC)Renal cell carcinoma (RCC)II
enfortumab vedotin / ASG-22MEantibody drug conjugate (ADC)Urothelial cancerII
erlotinib tabletsHER1/EGFR tyrosine kinase inhibitorVarious cancer typesIIGenentech / Roche
Xtandi® / enzalutamide (formerly MDV3100)oral androgen receptor antagonistBreast cancerIIMedivation
quizartinib (+ chemotherapy) / AC220FLT3 tyrosine kinase inhibitor1st line metastatic Acute Myelogenous Leukemia (AML)IAmbit Biosciences Inc.
AGS-16M8Fantibody drug conjugate (ADC)1st line metastatic Renal cell carcinoma (RCC)I
quizartinib / AC220FLT3 tyrosine kinase inhibitorAcute Myelogenous Leukemia (AML)IAmbit Biosciences Inc.
ASG-5MEantibody drug conjugate (ADC)Castrate-resistant Prostate cancer (CRPC)ISeattle Genetics
ASG-5MEantibody drug conjugate (ADC)Pancreatic cancerISeattle Genetics
OSI-027mTOR inhibitorVarious cancer typesIOSI Pharmaceuticals
OSI-930VEGFR-2 inhibitorVarious cancer typesI
ASP3026ALK inhibitorVarious cancer typesI
Xtandi® / enzalutamideoral androgen receptor antagonistHepatocellular carcinoma (HCC)I
enzalutamide / MDV3100androgen receptor inhibitorMetastatic castration-resistant Prostate cancerApproved

View additional information on product candidates here »

Source: http://www.astellas.us/

Recent News Headlines

5/27/2017 06:17 am

5/27/2017 06:17 am

5/27/2017 06:17 am

5/27/2017 06:17 am

5/27/2017 06:17 am

5/17/2017 06:17 pm

5/17/2017 06:17 pm

5/17/2017 06:17 pm

5/17/2017 06:17 pm

5/17/2017 06:17 pm

5/16/2017 06:17 pm

5/16/2017 06:17 pm

5/16/2017 06:17 pm

5/16/2017 06:17 pm

5/16/2017 06:17 pm

5/11/2017 06:17 am

5/11/2017 06:17 am

5/11/2017 06:17 am

5/10/2017 06:17 pm

4/28/2017 06:17 am

4/20/2017 06:17 am

Astellas to Acquire Ogeda SA

4/2/2017 11:03 pm

[PR Newswire] - TOKYO and GOSSELIES, Belgium, April 2, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Ogeda SA (CEO?Jean Combalbert, "Ogeda") ...

Astellas and Affinivax Announce Worldwide Partnership for MAPS Vaccine targeting Pneumococcal Disease

2/28/2017 10:00 am

[Business Wire] - CAMBRIDGE, Mass. & TOKYO--(BUSINESSWIRE)-- Affinivax, Inc. ("Affinivax") and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae (pneumococcus). The partnership will utilize Affinivax’s proprietary vaccine technology platform – Multiple Antigen Presenting System (MAPS) – to advance a novel MAPS vaccine targeted to prevent and reduce the spread of pneumococcal disease. “I am pleased to enter into this agreement and partner with Affinivax to develop a pneumococcal vaccine using their novel MAPS technology.” said Kenji Yasukawa, Ph.D., Senior Vice President and Chief Strategy Officer of Astellas.